Company: MLTX
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001140361-25-014923
Chunk: 22

Company: MoonLake Immunotherapeutics
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 22
---
 and affiliations, our Board has determined that Messrs. Sturge and Loy, Drs. Phillips and Xavier, and Ms. Moukheibir qualify as “independent directors” as defined by the Nasdaq listing rules. Dr. Santos da Silva is not deemed to be independent under Nasdaq listing rules by virtue of his employment with the Company. Former director Dr. Kara Lassen was independent under Nasdaq listing rules during the period she served on our Board. Our Board also determined that each of the directors currently serving on the Audit Committee and the Compensation Committee satisfy the additional independence criteria applicable to directors on such committees under Nasdaq listing rules and the rules and regulations established by the SEC. 13

TABLE OF CONTENTS

Board Committees Our Board has a separately designated Audit Committee, Compensation Committee and Nominating Committee, each of which has the composition and responsibilities described below. Members serve on these committees until their resignation or until otherwise determined by our Board. Each of these committees is empowered to retain outside advisors as it deems appropriate, regularly reports its activities to the full Board and has a written charter, which is posted on our website located at ir.moonlaketx.com, under “Corporate Governance”.

| Name                      |     |     Audit 
 Committee |     | Compensation 
    Committee |     | Nominating 
  Committee |
| Dr. Jorge Santos da Silva |     |           |     |              |     |            |
| Simon Sturge              |     |         X |     |              |     |      Chair |
| Spike Loy                 |     |         X |     |            X |     |            |
| Catherine Moukheibir      |     |     Chair |     |            X |     |            |
| Dr. Andrew Phillips       |     |           |     |        Chair |     |          X |
| Dr. Ramnik Xavier         |     |           |     |              |     |            |
| 

# of Meetings in 2024     |     |         4 |     |            2 |     |          2 |
Audit Committee . The primary responsibilities of our Audit Committee are to oversee the accounting and financial reporting processes of the Company, including the audits of the Company’s financial statements, the integrity of the financial statements and the annual review of the performance, effectiveness and independence of the outside auditor. This includes reviewing the financial information provided to shareholders and others and the adequacy and effectiveness of the Company’s internal controls. The committee also makes recommendations to the Board as to